Harbin Medical University Cancer
Welcome,         Profile    Billing    Logout  
 0 Trials 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Liu, Tong
NEOTORCH-BREAST01, NCT06611813: Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer

Recruiting
2
30
RoW
Neoadjuvant Chemotherapy in Combination with Toripalimab, HR+ HER2 breast cancer
First Affiliated Hospital of Zhejiang University
HR+/HER2- Breast Cancer
06/26
06/29
NEOTORCH-BREAST02, NCT06682195: Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC

Recruiting
2
35
RoW
Neoadjuvant chemotherapy combined with Toripalimab
First Affiliated Hospital of Zhejiang University
TNBC, Triple Negative Breast Cancer
10/26
10/29
NCT06851442: Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Not yet recruiting
1/2
75
RoW
TQB3912 tablets in combination with fulvestrant injection± TQB3616 capsules
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Breast Cancer
04/27
04/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Liu, Tong
NEOTORCH-BREAST01, NCT06611813: Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer

Recruiting
2
30
RoW
Neoadjuvant Chemotherapy in Combination with Toripalimab, HR+ HER2 breast cancer
First Affiliated Hospital of Zhejiang University
HR+/HER2- Breast Cancer
06/26
06/29
NEOTORCH-BREAST02, NCT06682195: Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC

Recruiting
2
35
RoW
Neoadjuvant chemotherapy combined with Toripalimab
First Affiliated Hospital of Zhejiang University
TNBC, Triple Negative Breast Cancer
10/26
10/29
NCT06851442: Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Not yet recruiting
1/2
75
RoW
TQB3912 tablets in combination with fulvestrant injection± TQB3616 capsules
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Breast Cancer
04/27
04/27

Download Options